



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Norman Nashed

Serial No.: 09/619,493

Group Art Unit: 1616

Filed: July 19, 2000

Examiner: S. Qazi

For: THERAPEUTIC GESTAGENS FOR THE TREATMENT OF PREMENSTRUAL
DYSPHORIC DISORDER

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97

Assistant Commissioner for Patents
Washington, D. C. 20231

Sir:

CITED MATERIALS

Applicant(s) wish to disclose the following information, listed in the attached form PTO-1449.

- Copies of materials listed but not attached (AA; AT-AW) were cited in parent application Serial No. 09/331,397.
- Copies of materials listed but not attached (AL-AN; AX) were cited in an International Search Report dated 7 September 1998 (attached); receipt of any International Search Report and copies of references were confirmed by the PCT International Division of the U.S. PTO in the Notice of Acceptance mailed 15 July 1999 in parent application, 09/331,397.
- Also included are the pending U.S. applications listed below, copies of which are attached:

FEES

- No fee is required for this Information Disclosure Statement because:
 - This Information Disclosure Statement is being filed within three months of the filing date of a national application (other than a CPA) under § 1.53(d) or within 3 months of the date of entry of the national stage under § 1.491 in an international application;
 - This Information Disclosure Statement is being filed before the mailing of a first action on the merits;
 - This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that closes prosecution in the application, and is accompanied by a certification below.

TECH CENTER 1600/2900
#214
RECEIVED
SEP 26 2001
28/09/2001

- A fee is required for this Information Disclosure Statement:
- This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311 or an action that closes prosecution, and is accompanied by the fee set forth in § 1.17(p).
- This Information Disclosure Statement is being filed after the mailing date of a final rejection or a notice of allowance under § 1.311 or an action that closes prosecution, but before the payment of the issue fee, and is accompanied by the fee set forth in § 1.17(p) and a certification below.

CERTIFICATION

- Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR § 1.56(c), more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

If appropriate, attached is a check in the amount of \$ _____. However, the Commissioner is hereby authorized to charge fees under 37 CFR 1.16 and 1.17 which may be required to facilitate this filing, or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Nancy Axelrod

Nancy J. Axelrod
Registration No. 44,014
Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza I
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410
Attorney Docket No.: SCH-1686 C1

Date: September 24, 2001

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. SCH 1686C1		APPLICATION SERIAL NO. 09/619,493	
LIST OF REFERENCES CITED BY APPLICANT <i>SEP 25 2001</i>		APPLICANT		Norman NASHED			
		FILING DATE July 19, 2000		GROUP 1616			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA	5,583,129	12/1996	Spona et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	NO	
	AL	0 640 343 A	3/1/1995	EPO			
	AM	43 13 926 A	11/3/1994	GERMANY			
	AN	43 44 462 A	6/29/1995	GERMANY			
	AO						
	AP						
	AQ						
	AR						
	AS						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AT	El-Sherbini, Abbas (CA 82:68681, abstract of Ain Shams Med, J. (1974), 25(4), 579-85), 1974.					
	AU	Boekler, H. (CA 78:24468, abstract of Sportarzt sportmed. (1972), 22(9), 233-4, 236-7, 1972.					
	AV	Neuman, Friedmund (CA 118:161077, abstract of Pharm. Ztg. (1992), 137(34), 9-15), 1992.					
	AW	Guenther et al. (CA 113:218253, abstract of WO 9004397), 1974.					
	AX	L.L. Altshuler et al.: "Pharmacological management of premenstrual disorder." HARVARD REV. PSYCHIAT. , BD 2 nR. 5, 1995, pages 233-245					
Examiner					Date Considered		
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							